<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01318837</url>
  </required_header>
  <id_info>
    <org_study_id>OABSSVSK-002</org_study_id>
    <nct_id>NCT01318837</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment</brief_title>
  <acronym>RESORT-2</acronym>
  <official_title>Reproducibility Study of OABSS and Its Response to Solifenacin Treatment (RESORT) and Validity in Korean Populations; Part 2: Responsiveness and Validity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate change of over active bladder symptom scores (OABSS) between,
      before and after solifenacin treatment to OAB subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline to week 4 in Over-Active Bladder Symptom Score (OABSS)</measure>
    <time_frame>week 0 (baseline) and week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline to week 12 in OABSS</measure>
    <time_frame>week 0 (baseline) and week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in International Prostate Symptom Score (IPSS) at week 4</measure>
    <time_frame>week 0 (baseline) and week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in IPSS at week 12</measure>
    <time_frame>week 0 (baseline) and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Quality of Life (QoL) Score at week 4</measure>
    <time_frame>week 0 (baseline) and week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in QoL Score at week 12</measure>
    <time_frame>week 0 (baseline) and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Patient Perception of Bladder Condition (PPBC) at week 4</measure>
    <time_frame>week 0 (baseline) and week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in PPBC at week 12</measure>
    <time_frame>week 0 (baseline) and week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Over Active Bladder</condition>
  <arm_group>
    <arm_group_label>sofilenacin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>age and sex matched patients without OAB symptom who will answer demographic questionaire and OABSS once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>solifenacin</intervention_name>
    <description>oral</description>
    <arm_group_label>sofilenacin group</arm_group_label>
    <other_name>Vesicare</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptoms of OAB for 3 months or longer

          -  At least 1 urgency episode in last 3 days

          -  Symptoms of OAB as verified by the screening 3-day bladder diary, defined by:

               -  a. Number of micturition ≥8 times/day

               -  b. Number of urgency episodes in 3 days ≥3

        Exclusion Criteria:

          -  Significant stress incontinence or mixed stress/urge incontinence

          -  Subject with indwelling catheters or practicing intermittent self-catheterization

          -  Symptomatic urinary tract infection, chronic inflammation

          -  Diabetic neuropathy

          -  Subjects who are prohibited from taking solifenacin as contraindications

          -  Drug or non-drug treatment for OAB was started, quitted or changed in 4 weeks

          -  Participation in any clinical trial in 30 days except for Part-1 of RESORT

          -  Diabetic neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bundang Seoul National University Hospital, Seong Jin Jeong, MD.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sungnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrSearch_e.jsp</url>
    <description>Link to Results on JAPIC - enter 140503 in the JapicCTI-RNo. field</description>
  </link>
  <reference>
    <citation>Jeong SJ, Homma Y, Oh SJ. Reproducibility study of Overactive Bladder Symptom Score questionnaire and its response to treatment (RESORT) in Korean population with overactive bladder symptoms. Qual Life Res. 2014 Feb;23(1):285-92. doi: 10.1007/s11136-013-0440-7. Epub 2013 May 29.</citation>
    <PMID>23715806</PMID>
  </reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2011</study_first_submitted>
  <study_first_submitted_qc>March 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2011</study_first_posted>
  <last_update_submitted>July 9, 2014</last_update_submitted>
  <last_update_submitted_qc>July 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OABSS</keyword>
  <keyword>IPSS</keyword>
  <keyword>PPBC</keyword>
  <keyword>Solifenacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

